HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $280
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $195 to $280.
HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $195 to $280.